Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Breast Cancer Research

Fig. 1

From: Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis

Fig. 1

Co-culture of MDA-MB-231-LN cells with lymphatic endothelial cells (LECs) promotes cell proliferation, which is inhibited by tocilizumab. a Schematic diagram of co-cultured MDA-MB-231-LN cells with LECs (RTCA system, ACEA Biosciences Inc.). b Proliferation assays of co-cultured MDA-MB-231-LN cells on the bottom chambers with LECs (10,000 cells per well) on the top chamber were performed for 3 days. Cells were trypsinized and manually counted with a hemocytometer. Results are means ± SEM (n = 3). c Cellular viability assays of co-cultured MDA-MB-231-LN cells on the bottom chambers with LECs on the top chamber in treatment with various concentration of maraviroc and d tocilizumab (E-plates). The bottom and top chambers were combined, loaded in the RTCA system and the cell index was measured continuously for 48 h (*P < 0.001, n = 3). e The same assay was performed as in d in treatment with maraviroc (2 uM) (M), tocilizumab (200 μg/ml; 135 uM) (T), and the combination of maraviroc and tocilizumab (M+T); Veh, Vehicle. f Crystal violet staining assay was performed as in e

Back to article page